Phathom Pharmaceuticals (PHAT) Notes Payables (2018 - 2019)
Phathom Pharmaceuticals (PHAT) posted quarterly Notes Payables of $95.2 million for Q3 2019, up 4783.54% quarter-over-quarter from $2.0 million in Q4 2018.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Notes Payables (2018 - 2019) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Notes Payables for 2 consecutive years, with $95.2 million the latest figure, recorded in Q3 2019.
- In Q3 2019, Notes Payables changed N/A year-over-year to $95.2 million; the TTM figure through Sep 2019 stood at $95.2 million (changed N/A YoY), while the FY2018 annual figure was $2.0 million, changed N/A from the prior year.
- Notes Payables rose to $95.2 million in Q3 2019 per PHAT's latest filing, from $2.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $95.2 million in Q3 2019 and bottomed at $2.0 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn |